Spruce Biosciences (SPRB) Long-Term Debt Issuances (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Long-Term Debt Issuances of $14.1 million for Q1 2026, up 183.49% quarter-over-quarter from $5.0 million in Q1 2021.
Spruce Biosciences (SPRB) Long-Term Debt Issuances (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Long-Term Debt Issuances for 3 consecutive years, with $14.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (changed N/A YoY), while the FY2021 annual figure was $5.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances rose to $14.1 million in Q1 2026 per SPRB's latest filing, from $5.0 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $14.1 million in Q1 2026 and bottomed at $14.1 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.15 Mn |
| Mar 31, 2026 | 14.15 Mn |
| Mar 31, 2021 | 4.99 Mn |
| Mar 31, 2021 | 4.99 Mn |
| Dec 31, 2019 | 2.00 Mn |
| Dec 31, 2019 | 2.00 Mn |
| Sep 30, 2019 | 2.50 Mn |
| Sep 30, 2019 | 2.50 Mn |